Review
|
Open Access
Featured
-
-
Translational Therapeutics
| Open AccessLurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
- Cristina Belgiovine
- , Ezia Bello
- & Maurizio D'Incalci
-
Clinical Study
| Open AccessA phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
- Glen J Weiss
- , Jordan Waypa
- & Vivek Khemka
-
Translational Therapeutics
| Open AccessEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases
- Sagun Parakh
- , John J Park
- & Matteo S Carlino
-
Mini Review
| Open AccessHallmarks of response to immune checkpoint blockade
- Alexandria P Cogdill
- , Miles C Andrews
- & Jennifer A Wargo
-
Epidemiology
| Open AccessStatin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study
- Ronan T Gray
- , Maurice B Loughrey
- & Helen G Coleman
-
Clinical Study
| Open AccessSecond-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
- F Koinis
- , S Agelaki
- & A Kotsakis
-
Clinical Study
| Open AccessEfficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data
- Chikuma Hamada
- , Takuji Okusaka
- & Shota Okamura
-
Clinical Study
| Open AccessPhase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
- Rastislav Bahleda
- , Juneko E Grilley-Olson
- & Jean-Charles Soria
-
Clinical Study
| Open AccessThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Clinical Study
| Open AccessA phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
- M A Calegari
- , A Inno
- & C Barone
-
Translational Therapeutics
| Open AccessPretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
- Didier Meulendijks
- , Linda M Henricks
- & Jan H M Schellens
-
Translational Therapeutics
| Open AccessCharacterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy
- Amir Faisal
- , Grace W Y Mak
- & Spiros Linardopoulos
-
Letter to the Editor
| Open AccessReply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
- Samantha Bowyer
- , Prashanth Prithviraj
- & Oliver Klein
-
Clinical Study
| Open AccessCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
- Roberto Pili
- , Glenn Liu
- & Michael A Carducci
-
Clinical Study
| Open AccessA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
- Richard H Wilson
- , TR Jeffry Evans
- & Ruth Plummer
-
Short Communication
| Open AccessCombined oral contraceptive use before the first birth and epithelial ovarian cancer risk
- Linda S Cook
- , Claire R Pestak
- & Nhu Le
-
Letter to the Editor |
Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Luca Mascitelli
- & Mark R Goldstein
-
Letter to the Editor |
Reply to Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Ange Wang
- , Aaron K Aragaki
- & Marcia L Stefanick
-
Epidemiology
| Open AccessReproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Initiative Observational Study
- Neil Murphy
- , Linzhi Xu
- & Marc J Gunter
-
Editorial
| Open AccessTrastuzumab cardiotoxiciy: the age-old balance of risk and benefit
- Michael S Ewer
- & Steven M Ewer
-
Clinical Study
| Open AccessCaphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
- Nathaniel Treister
- , Michael Nieder
- & Lillian Sung
-
Translational Therapeutics
| Open AccessAn individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
- Lishuang Qi
- , Yang Li
- & Zheng Guo
-
Epidemiology
| Open AccessThe use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer
- Victoria Mandilaras
- , Nathaniel Bouganim
- & Laurent Azoulay
-
Clinical Study
| Open AccessQuality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
- Jonathan A Ledermann
- , Philipp Harter
- & Ursula Matulonis
-
Clinical Study
| Open AccessPredictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
- Faidon-Marios Laskaratos
- , Martin Walker
- & Christos Toumpanakis
-
Clinical Study
| Open AccessRandomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- Angus G Dalgleish
- , Justin Stebbing
- & Satvinder S Mudan
-
Epidemiology
| Open AccessStatin use and all-cancer survival: prospective results from the Women’s Health Initiative
- Ange Wang
- , Aaron K Aragaki
- & Marcia L Stefanick
-
-
Letter to the Editor
| Open AccessComment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’
- Caterina Vivaldi
- , Lorenzo Fornaro
- & Enrico Vasile
-
Letter to the Editor
| Open AccessReply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’
- Simon Pernot
- , Jean-Baptiste Bachet
- & Julien Taieb
-
Clinical Study
| Open AccessEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- S Bowyer
- , P Prithviraj
- & O Klein
-
Epidemiology
| Open AccessThe effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients
- Jente van Staalduinen
- , Martine Frouws
- & Gerrit-Jan Liefers
-
Editorial
| Open AccessPARP inhibitors: the race is on
- Jessica S Brown
- , Stan B Kaye
- & Timothy A Yap
-
Epidemiology
| Open AccessAnalgesic medication use and risk of epithelial ovarian cancer in African American women
- Lauren C Peres
- , Fabian Camacho
- & Joellen M Schildkraut
-
Short Communication
| Open AccessChetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
- Elena Viziteu
- , Camille Grandmougin
- & Jerome Moreaux
-
Clinical Study
| Open AccessPhase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
- K Yong
- , J Cavet
- & J Cavenagh
-
Mini Review |
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
- Jonathan A Ledermann
- & Fatima El-Khouly
-
Clinical Study
| Open AccessA phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- Jeong-Hoon Lee
- , Yoon Lee
- & Yoon Jun Kim
-
Clinical Study
| Open AccessPredictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
- Christoph Zielinski
- , Istvan Lang
- & Thomas Brodowicz
-
Translational Therapeutics
| Open AccessIncreased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
- B Colmegna
- , S Uboldi
- & M D'Incalci
-
Clinical Study
| Open AccessA phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
- S Lheureux
- , A M Oza
- & R Goel
-
Clinical Study
| Open AccessPhase I study of afatinib combined with nintedanib in patients with advanced solid tumours
- Rastislav Bahleda
- , Antoine Hollebecque
- & Jean-Charles Soria
-
Clinical Study
| Open AccessA randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
- S H Lim
- , T W Kim
- & W K Kang
-
Clinical Study
| Open AccessA randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
- T Eisen
- , A-B Loembé
- & I Bondarenko
-
Clinical Study
| Open AccessNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- Alix Portal
- , Simon Pernot
- & Julien Taieb
-
Letter to the Editor
| Open AccessComment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’
- Susannah Ellsworth
- & Stuart A Grossman
-
Letter to the Editor
| Open AccessResponse to: Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’
- Eric T Wong
- & Kenneth D Swanson
-
Clinical Study
| Open AccessLong-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
- Ruud van der Noll
- , Serena Marchetti
- & Jan H M Schellens
-
Clinical Study
| Open AccessClinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
- Nathalie Quenel-Tueux
- , Marc Debled
- & Richard Iggo